Me



Docket No.: 20718/1204135-US3 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Letters Patent of: Eugenio A. Cefali et al.

Patent No.: 6,818,229

Issued: November 16, 2004

For: INTERMEDIATE RELEASE NICOTINIC ACID COMPOSITIONS FOR TREATING

HYPERLIPIDEMIA

Certificate

SEP 2 A 2006

Of Correct

REQUEST FOR CERTIFICATE OF CORRECTION PURSUANT TO 37 CFR 1.323

Attention: Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:


Upon reviewing the above-identified patent, Patentee noted typographical errors which should be corrected.

In the Specification:

At Figure Sheet 5 of 5, please replace Fig. 5 with the following corrected replacement figure:

OCT - 2 2006

53757.5005 TREET 20000057 8555955



At column 2, line 67, please delete the phrase "18 or 78 percent" and insert the phrase --12 or 52 percent --.

At column 27, line 46, please delete the phrase "had 18 of 23, or 78 percent" and insert the phrase --had 12 of 23, or 52 percent--.

· - 2 600

At column 27, please replace Table VIII with the following corrected replacement table:

TABLE VIII
A Comparison of Changes in Liver Function Tests

				DC	SE			
	0	500	1000	1500	2000	2500	3000	TOTAL
McKenn	ey SR ^b Niacin	1		•				
AST	23.8	27.9	40.4	36.6	56.5	na	97.0	
%		117	170	154	237	na	408	
Invention	n Dosage ^c							
AST	24.3	na	23.7	27.5	26.6	27.6	27.8	l
%		na	98	113	109	114	114	
McKenn	ey SR Niacin	<u> </u>					·	
AST	25.6	29.5	36.3	39.0	59.1	na	100.0	
%		115	142	152	231	na	391	
Inventio	n Dosage							
ALT	21.4	na	18.7	22.6	21.3	22.4	21.8	
%		na	87	106	100	105	102	
McKenn	ey SR Niacin	 -						
ALK	95	95	106	105	136	na	135	
%		100	112	111	143	na	142	
Inventio	n Dosage		•					
ALK	74.7	na	73.9	76.1	73.4	76.7	78.0	
%		na	99	102	98	103	104	
McKenn	ey SR Niacin							
Drop		0	1	2	4	na	5	12
n								23
%		0	4	9	17	na	22	52
Inventio	n Dosage					•		· · · · · · · · · · · · · · · · · · ·
Drop			0	0	0	0	0	0
n			26	67	97	35	15	240
%			0	0	0	0	0	0
1 year			15	47	77	31	15	184
1 year			58	69	79	89	100	77

Dosed twice-per-day as described in "A Comparison of the Efficacy and Toxic Effects of Sustained - vs. Immediate - Release Niacin in Hypercholesterolemic Patients" by McKenney et al., *Journal of the American Medical Association*, March 2, 1994; Vol. 271, No. 9, pages 672-677.

^b SR is "sustained release"

^c Dosed once-per-day at night

Patent No.: 6,818,229 4 Docket No.: 20718/1204135-US3

Remarks:

The errors were found in the application as filed by applicant. The errors now sought to be corrected are inadvertent typographical errors, the correction of which does not involve new

matter or require reexamination.

Our check in the amount of \$100.00 covering the fee set forth in 37 CFR 1.20(a) is

enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any

excess in this fee to Deposit Account No. 04-0100.

Transmitted herewith is a proposed Certificate of Correction effecting such amendment.

Patentee respectfully solicits the granting of the requested Certificate of Correction.

Dated: September 21, 2006

Respectfully submitted,

Bv:

Paul M. Zagar, M.D. Reg. No. 52,392

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700 (Tel.)

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO.

6,818,229

APPLICATION NO.

08/962,027

ISSUE DATE


November 16, 2004


INVENTOR(S)

Eugenio A. Cefali et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At Figure Sheet 5 of 5, please replace Fig. 5 with the following corrected replacement figure:





PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

	At column 2, line 67, please delete the phrase "18 or 78 percent" and insert the
	phrase12 or 52 percent
	At column 27, line 46, please delete the phrase "had 18 of 23, or 78 percent"
	and insert the phrasehad 12 of 23, or 52 percent
į	

· 2 2006.

Patent No.: 6,818,229

PTO/SB/44 (04-05)
Approved for use through 04/30/2007. OMB 0651-0033
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

(Also Form PTO-1050)

At column 27, please replace Table VIII with the following corrected replacement

table:

TABLE VIII A Comparison of Changes in Liver Function Tests

		DOSE						
	0	500	1000	1500	2000	2500	3000	TOTAL
McKenney S	SR ^b Niacin							
AST	23.8	27.9	40.4	36.6	56.5	na	97.0	
%		117	170	154	237	na	408	
Invention D	osage ^c							
AST	24.3	па	23.7	27.5	26.6	27.6	27.8	
%		na	98	113	109	114	114	
McKenney S	SR Niacin				•			
AST	25.6	29.5	36.3	39.0	59.1	na	100.0	
%		115	142	152	231	na	391	
Invention D	osage						•	
ALT	21.4	па	18.7	22.6	21.3	22.4	21.8	
%		na	87	106	100	105	102	
McKenney S	SR Niacin							•
ALK	95	95	106	105	136	na	135	
%		100	112	111	143	na	142	
Invention D	osage							
ALK	74.7	na	73.9	76.1	73.4	76.7	78.0	1
%		na	99	102	98	103	104	
McKenney 8	SR Niacin							
Drop		0	1	2	4	na	5	12
n								23
%		0	4	9	17	na	22	52
Invention D	osage		1	•			•	
Drop			0	0	0	0	0	0
n			26	67	97	35	15	240
%			0	0	0	0	0	0
1 year			15	47	77	31	15	184
1 year			58	69	79	89	100	77

Dosed twice-per-day as described in "A Comparison of the Efficacy and Toxic Effects of Sustained - vs. Immediate - Release Niacin in Hypercholesterolemic Patients" by McKenney et al., Journal of the American Medical Association, March 2, 1994; Vol. 271, No. 9, pages 672-677.

- 2 2008

Patent No.: 6,818,229

^b SR is "sustained release"

^c Dosed once-per-day at night



Application No. (if known): 08/962,027

Attorney Docket No.: 20718/1204135-US3

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. _____ in an envelope addressed to:

EV834732721 - US

Attention: Certificate of Correction Branch Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	September 21, 2006					
	Date					

	Kellian &	Yanein .
	Lillian Ga	5619
	Typed or printed name of person	signing Certificate
Regi	stration Number, if applicable	Telephone Number
Note:	Each paper must have its own certificate of m each submitted paper.	ailing, or this certificate must identify
	Fee Transmittal (1 page);	· Dagwigad) (4 magaz)

Fee Transmittal (1 page);
Request for Certificate of Correction (Fee Required) (4 pages);
Certificate of Correction (3 pages);
Check in the amount of \$100.00; and
Return Receipt Postcard.

PTO/SB/17 (07-06)

Approved for use through 01/31/2007. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Output the Repeated Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control unless.

§ 1 300g

Under the Paperwork Reduction Act of 1995, no person are required to respond to a collection of information unless it displays a valid OMB control number. Complete if Known Effective on 12/08/2004. Patent#: 6,818,229 es pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818). **Application Number** FEE TRANSMITTAL Filing Date Issued: November 16, 2004 Eugenio A. Cefali First Named Inventor For FY 2005 Examiner Name Robert M. Joynes Applicant claims small entity status. See 37 CFR 1.27 N/A Art Unit 20718/1204135-US3 TOTAL AMOUNT OF PAYMENT 100.00 Attorney Docket No. METHOD OF PAYMENT (check all that apply) Check Money Order х Credit Card None Other (please identify): Darby & Darby P.C. Deposit Account Number: 04-0100 Deposit Account Name: For the above-identified deposit account, the Director is hereby authorized to: (check all that apply) Charge fee(s) indicated below Charge fee(s) indicated below, except for the filing fee Charge any additional fee(s) or underpayment of Credit any overpayments fee(s) under 37 CFR 1.16 and 1.17 **FEE CALCULATION** 1. BASIC FILING, SEARCH, AND EXAMINATION FEES **FILING FEES** SEARCH FEES **EXAMINATION FEES Small Entity Small Entity** Small Entity **Application Type** Fee (\$) Fee (\$) Fee (\$) Fees Paid (\$) Fee (\$) Fee (\$) Fee (\$) Utility 300 100 150 500 250 200 Design 200 100 100 50 130 65 Plant 200 100 300 150 80 160 Reissue 300 150 500 250 600 300 Provisional 200 100 n n 0 n 2. EXCESS CLAIM FEES **Small Entity** Fee (\$) Fee (\$) Fee Description Each claim over 20 (including Reissues) 50 25 Each independent claim over 3 (including Reissues) 200 100 Multiple dependent claims 180 360 **Total Claims** Extra Claims Fee Paid (\$) **Multiple Dependent Claims** Fee (\$) Fee (\$) Fee Paid (\$) HP = highest number of total claims paid for, if greater than 20. Indep. Claims **Extra Claims** Fee (\$) Fee Paid (\$) HP = highest number of independent claims paid for, if greater than 3. 3. APPLICATION SIZE FEE If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s). Fee Paid (\$) Extra Sheets Number of each additional 50 or fraction thereof Fee (\$) - 100 = /50 (round up to a whole number) x 4. OTHER FEE(S) Fees Paid (\$) Non-English Specification, \$130 fee (no small entity discount) Other (e.g., late filing surcharge): 1811 Certificate of correction 100.00 SUBMITTED BY Registration No. (Attorney/Agent) Signature 52,392 Telephone (212) 527-7700 Paul M. Zagar Name (Print/Type) September 21, 2006 Date